Entellus Medical Inc (ENTL) 27.43 $ENTL
Entellus Medical to Report First Quarter 2015 Financial Results on May 7, 2015
GlobeNewswire - Thu Apr 23, 3:05PM CDT
Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced that it will release its financial results for the first quarter of 2015 after the close of trading on Thursday, May 7, 2015. The Company's management team will host a corresponding conference call beginning at 3:30pm CT/4:30pm ET to discuss the financial results and recent business developments.
ENTL: 27.43 (+0.44)
Here Are The Top Performing IPOs In The First Quarter
at Investor's Business Daily - Fri Apr 03, 7:02AM CDT
The health care sector, which had the most initial public offerings of 2014, continued a hot pace in the first quarter. Spark Therapeutics (ONCE) was the top IPO winner in the first quarter, with a 237% return. The biotech developer of gene therapy...
BOX: 17.75 (-0.53), SHAK: 68.53 (+5.80), ONCE: 61.39 (-0.66), ENTL: 27.43 (+0.44), TCON: 11.74 (-0.41)
New chief at Entellus Med
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 3:21PM CDT
ENTL: 27.43 (+0.44)
Entellus Medical Announces Promotion of Robert White to Chief Executive Officer, and Preliminary First Quarter 2015 Revenues of $13.4 to $13.5 Million
GlobeNewswire - Thu Apr 02, 3:05PM CDT
Entellus Medical, Inc. ("Entellus Medical" or the "Company"
(Nasdaq:ENTL), a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, announced that effective today, Robert White, President and Chief Operating Officer of the Company has been promoted to President and Chief Executive Officer and appointed to its Board of Directors. In a planned move, Brian Farley, the Company's current Chairman and Chief Executive Officer, has transitioned to Executive Chairman of the Board and part-time employment with the Company.
ENTL: 27.43 (+0.44)
Entellus reports Q4 results
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 3:19PM CDT
ENTL: 27.43 (+0.44)
Entellus Medical Announces Fourth Quarter and Full Year 2014 Financial Results and Provides 2015 Financial Outlook
GlobeNewswire - Tue Mar 17, 3:02PM CDT
Entellus Medical, Inc. ("Entellus Medical" or the "Company" (Nasdaq:ENTL), a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today reported its financial results for the three months and year ended December 31, 2014.
ENTL: 27.43 (+0.44)
IPO Quiet Period Expiration: Entellus Medical Inc.
Don Dion - at Seeking Alpha - Wed Feb 18, 6:16PM CST
ENTL: 27.43 (+0.44)
Entellus Medical Announces Release of XprESS(TM) Ultra Multi-Sinus Dilation System
GlobeNewswire - Fri Feb 13, 6:00AM CST
Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced the release of the XprESS(TM) Ultra Multi-Sinus Dilation System, the third device in the XprESS family of balloon sinus dilation systems.
ENTL: 27.43 (+0.44)
InsiderInsights.com Daily Round Up 2/4/15: BZH, MLNK, CDNA, FDBC
InsiderInsights - at Seeking Alpha - Thu Feb 05, 6:39AM CST
LBTYK: 50.95 (+0.44), CRR: 31.60 (-1.26), SLG: 128.82 (+1.47), BBY: 35.39 (-0.74), MLNK: 3.66 (-0.05), BZH: 17.69 (+0.35), QVCA: 29.42 (+0.11), BA: 148.40 (-1.47), OCUL: 25.36 (-1.12), LMCA: 39.40 (+0.60), OPK: 14.83 (+0.17), CDNA: 5.13 (-0.12), ENTL: 27.43 (+0.44), MSFT: 47.87 (+4.53), SCHW: 30.12 (-0.38)
Entellus Medical, Inc. Announces Closing of Initial Public Offering
GlobeNewswire - Tue Feb 03, 3:18PM CST
Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, announced today the closing of its initial public offering of 5,294,117 shares of its common stock (including 690,537 shares purchased by the underwriters pursuant to an option to purchase additional shares) at a public offering price of $17.00 per share, resulting in gross proceeds of approximately $90.0 million before underwriting discounts and commissions. The shares began trading on The NASDAQ Global Market under the ticker symbol "ENTL" on January 29, 2015.
ENTL: 27.43 (+0.44)
U.S. IPO Weekly Recap: Shake Shack And Spark Spike Over 100% In A Week With 10 IPOs
Renaissance Capital IPO Research - at Seeking Alpha - Sun Feb 01, 7:41AM CST
Ten IPOs raised $1.2 billion in a week dominated by 8 health care IPOs and distinguished by 2 deals that gained over 100% on the first day - fast casual burger chain Shake Shack and gene therapy biotech Spark Therapeutics. There were more health care...
AVGR: 11.82 (+0.20), SHAK: 68.53 (+5.80), ASND: 20.00 (-0.86), HIFR: 31.27 (-0.37), ONCE: 61.39 (-0.66), ENTL: 27.43 (+0.44), ZSAN: 8.80 (-0.10), LENS: 7.38 (-0.62), FLKS: 22.56 (-0.35), TCON: 11.74 (-0.41)
Nasdaq Welcomes Entellus Medical, Inc. (Nasdaq: ENTL) to The Nasdaq Stock Market
GlobeNewswire - Thu Jan 29, 11:59AM CST
Nasdaq (Nasdaq:NDAQ) announced that trading of Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company, commenced on The Nasdaq Stock Market on January 29, 2015.
ENTL: 27.43 (+0.44), NDAQ: 48.57 (-1.19)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 11:47AM CST
CRMD: 8.61 (-0.22), FRO: 2.71 (-0.09), NES: 3.80 (-0.07), SILC: 44.20 (+1.71), GNCA: 12.24 (-0.26), NBG: 1.23 (+0.06), APPY: 0.56 (+0.01), LRN: 15.51 (-0.76), SR: 0.91 (-0.12), DSKY: 9.80 (+0.03), GENE: 4.70 (-0.13), SMLR: 3.75 (+0.34), PFMT: 3.22 (-0.04), QCOM: 68.24 (-0.10), PSTR: 4.58 (-0.05), ENTL: 27.43 (+0.44), ATTU: 10.79 (+0.41), CTP: 3.90 (-0.12), LENS: 7.38 (-0.62), RCON: 1.90 (-0.10)
Entellus Medical (ENTL) Stock Up Today on Trading Debut After Pricing IPO at $17
at The Street - Thu Jan 29, 11:14AM CST
Shares of Entellus Medical (ENTL) are rising as the medical technology company begins trading on the NASDAQ Global Market after pricing its IPO at $17 per share.
ENTL: 27.43 (+0.44)
Entellus Medical, Inc. (Nasdaq:ENTL) to Ring The Nasdaq Stock Market Closing Bell in Celebration of IPO
GlobeNewswire - Thu Jan 29, 5:00AM CST
What:
ENTL: 27.43 (+0.44), NDAQ: 48.57 (-1.19)
IPO Report: Entellus Medical
IPOdesktop - at Seeking Alpha - Thu Jan 29, 12:39AM CST
Based in Plymouth, MN, Entellus Medical (Pending: ENTL ) scheduled a $70 million IPO on Nasdaq with a market capitalization of $279 million at a price range midpoint of $16 for Thursday, Jan. 29, 2015. Priced at $17, no change in conclusion. The...
ENTL: 27.43 (+0.44)
Entellus prices IPO
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 9:04PM CST
ENTL: 27.43 (+0.44)
Entellus Medical, Inc. Announces Pricing of Initial Public Offering
GlobeNewswire - Wed Jan 28, 8:32PM CST
Entellus Medical, Inc., a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, announced today the pricing of its initial public offering of 4,603,580 shares of its common stock at an initial public offering price of $17.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Market under the ticker symbol "ENTL" on January 29, 2015. In addition, Entellus Medical has granted the underwriters a 30-day option to purchase up to an additional 690,537 shares of common stock at the same price. The offering is expected to close on February 3, 2015, subject to customary closing conditions.
ENTL: 27.43 (+0.44)
Entellus Medical IPO: No Headaches Here
Don Dion - at Seeking Alpha - Wed Jan 28, 2:40PM CST
ENTL: 27.43 (+0.44)
Week Ahead: IPO Market Gains Momentum With 12 Deals Including Shake Shack And Health Care
Renaissance Capital IPO Research - Seeking Alpha - Tue Jan 27, 7:03AM CST
Twelve IPOs are set to raise $1 billion in the upcoming week, which would make it the busiest five-day stretch for IPOs since the week of July 28. Shake Shack's IPO offers investors a chance to own a fast-growing fast casual concept based in New...
AVGR: 11.82 (+0.20), SHAK: 68.53 (+5.80), ASND: 20.00 (-0.86), HIFR: 31.27 (-0.37), REDX: (), ONCE: 61.39 (-0.66), ENTL: 27.43 (+0.44), ZSAN: 8.80 (-0.10), FLKS: 22.56 (-0.35), LENS: 7.38 (-0.62), TCON: 11.74 (-0.41)
Entellus Medical to Report First Quarter 2015 Financial Results on May 7, 2015
GlobeNewswire - Thu Apr 23, 3:05PM CDT
Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced that it will release its financial results for the first quarter of 2015 after the close of trading on Thursday, May 7, 2015. The Company's management team will host a corresponding conference call beginning at 3:30pm CT/4:30pm ET to discuss the financial results and recent business developments.
ENTL: 27.43 (+0.44)
Here Are The Top Performing IPOs In The First Quarter
at Investor's Business Daily - Fri Apr 03, 7:02AM CDT
The health care sector, which had the most initial public offerings of 2014, continued a hot pace in the first quarter. Spark Therapeutics (ONCE) was the top IPO winner in the first quarter, with a 237% return. The biotech developer of gene therapy...
BOX: 17.75 (-0.53), SHAK: 68.53 (+5.80), ONCE: 61.39 (-0.66), ENTL: 27.43 (+0.44), TCON: 11.74 (-0.41)
New chief at Entellus Med
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 3:21PM CDT
ENTL: 27.43 (+0.44)
Entellus Medical Announces Promotion of Robert White to Chief Executive Officer, and Preliminary First Quarter 2015 Revenues of $13.4 to $13.5 Million
GlobeNewswire - Thu Apr 02, 3:05PM CDT
Entellus Medical, Inc. ("Entellus Medical" or the "Company"
(Nasdaq:ENTL), a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, announced that effective today, Robert White, President and Chief Operating Officer of the Company has been promoted to President and Chief Executive Officer and appointed to its Board of Directors. In a planned move, Brian Farley, the Company's current Chairman and Chief Executive Officer, has transitioned to Executive Chairman of the Board and part-time employment with the Company. ENTL: 27.43 (+0.44)
Entellus reports Q4 results
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 3:19PM CDT
ENTL: 27.43 (+0.44)
Entellus Medical Announces Fourth Quarter and Full Year 2014 Financial Results and Provides 2015 Financial Outlook
GlobeNewswire - Tue Mar 17, 3:02PM CDT
Entellus Medical, Inc. ("Entellus Medical" or the "Company"
(Nasdaq:ENTL), a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today reported its financial results for the three months and year ended December 31, 2014. ENTL: 27.43 (+0.44)
IPO Quiet Period Expiration: Entellus Medical Inc.
Don Dion - at Seeking Alpha - Wed Feb 18, 6:16PM CST
ENTL: 27.43 (+0.44)
Entellus Medical Announces Release of XprESS(TM) Ultra Multi-Sinus Dilation System
GlobeNewswire - Fri Feb 13, 6:00AM CST
Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced the release of the XprESS(TM) Ultra Multi-Sinus Dilation System, the third device in the XprESS family of balloon sinus dilation systems.
ENTL: 27.43 (+0.44)
InsiderInsights.com Daily Round Up 2/4/15: BZH, MLNK, CDNA, FDBC
InsiderInsights - at Seeking Alpha - Thu Feb 05, 6:39AM CST
LBTYK: 50.95 (+0.44), CRR: 31.60 (-1.26), SLG: 128.82 (+1.47), BBY: 35.39 (-0.74), MLNK: 3.66 (-0.05), BZH: 17.69 (+0.35), QVCA: 29.42 (+0.11), BA: 148.40 (-1.47), OCUL: 25.36 (-1.12), LMCA: 39.40 (+0.60), OPK: 14.83 (+0.17), CDNA: 5.13 (-0.12), ENTL: 27.43 (+0.44), MSFT: 47.87 (+4.53), SCHW: 30.12 (-0.38)
Entellus Medical, Inc. Announces Closing of Initial Public Offering
GlobeNewswire - Tue Feb 03, 3:18PM CST
Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, announced today the closing of its initial public offering of 5,294,117 shares of its common stock (including 690,537 shares purchased by the underwriters pursuant to an option to purchase additional shares) at a public offering price of $17.00 per share, resulting in gross proceeds of approximately $90.0 million before underwriting discounts and commissions. The shares began trading on The NASDAQ Global Market under the ticker symbol "ENTL" on January 29, 2015.
ENTL: 27.43 (+0.44)
U.S. IPO Weekly Recap: Shake Shack And Spark Spike Over 100% In A Week With 10 IPOs
Renaissance Capital IPO Research - at Seeking Alpha - Sun Feb 01, 7:41AM CST
Ten IPOs raised $1.2 billion in a week dominated by 8 health care IPOs and distinguished by 2 deals that gained over 100% on the first day - fast casual burger chain Shake Shack and gene therapy biotech Spark Therapeutics. There were more health care...
AVGR: 11.82 (+0.20), SHAK: 68.53 (+5.80), ASND: 20.00 (-0.86), HIFR: 31.27 (-0.37), ONCE: 61.39 (-0.66), ENTL: 27.43 (+0.44), ZSAN: 8.80 (-0.10), LENS: 7.38 (-0.62), FLKS: 22.56 (-0.35), TCON: 11.74 (-0.41)
Nasdaq Welcomes Entellus Medical, Inc. (Nasdaq: ENTL) to The Nasdaq Stock Market
GlobeNewswire - Thu Jan 29, 11:59AM CST
Nasdaq (Nasdaq:NDAQ) announced that trading of Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company, commenced on The Nasdaq Stock Market on January 29, 2015.
ENTL: 27.43 (+0.44), NDAQ: 48.57 (-1.19)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 11:47AM CST
CRMD: 8.61 (-0.22), FRO: 2.71 (-0.09), NES: 3.80 (-0.07), SILC: 44.20 (+1.71), GNCA: 12.24 (-0.26), NBG: 1.23 (+0.06), APPY: 0.56 (+0.01), LRN: 15.51 (-0.76), SR: 0.91 (-0.12), DSKY: 9.80 (+0.03), GENE: 4.70 (-0.13), SMLR: 3.75 (+0.34), PFMT: 3.22 (-0.04), QCOM: 68.24 (-0.10), PSTR: 4.58 (-0.05), ENTL: 27.43 (+0.44), ATTU: 10.79 (+0.41), CTP: 3.90 (-0.12), LENS: 7.38 (-0.62), RCON: 1.90 (-0.10)
Entellus Medical (ENTL) Stock Up Today on Trading Debut After Pricing IPO at $17
at The Street - Thu Jan 29, 11:14AM CST
Shares of Entellus Medical (ENTL) are rising as the medical technology company begins trading on the NASDAQ Global Market after pricing its IPO at $17 per share.
ENTL: 27.43 (+0.44)
Entellus Medical, Inc. (Nasdaq:ENTL) to Ring The Nasdaq Stock Market Closing Bell in Celebration of IPO
GlobeNewswire - Thu Jan 29, 5:00AM CST
What:
ENTL: 27.43 (+0.44), NDAQ: 48.57 (-1.19)
IPO Report: Entellus Medical
IPOdesktop - at Seeking Alpha - Thu Jan 29, 12:39AM CST
Based in Plymouth, MN, Entellus Medical (Pending: ENTL ) scheduled a $70 million IPO on Nasdaq with a market capitalization of $279 million at a price range midpoint of $16 for Thursday, Jan. 29, 2015. Priced at $17, no change in conclusion. The...
ENTL: 27.43 (+0.44)
Entellus prices IPO
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 9:04PM CST
ENTL: 27.43 (+0.44)
Entellus Medical, Inc. Announces Pricing of Initial Public Offering
GlobeNewswire - Wed Jan 28, 8:32PM CST
Entellus Medical, Inc., a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, announced today the pricing of its initial public offering of 4,603,580 shares of its common stock at an initial public offering price of $17.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Market under the ticker symbol "ENTL" on January 29, 2015. In addition, Entellus Medical has granted the underwriters a 30-day option to purchase up to an additional 690,537 shares of common stock at the same price. The offering is expected to close on February 3, 2015, subject to customary closing conditions.
ENTL: 27.43 (+0.44)
Entellus Medical IPO: No Headaches Here
Don Dion - at Seeking Alpha - Wed Jan 28, 2:40PM CST
ENTL: 27.43 (+0.44)
Week Ahead: IPO Market Gains Momentum With 12 Deals Including Shake Shack And Health Care
Renaissance Capital IPO Research - Seeking Alpha - Tue Jan 27, 7:03AM CST
Twelve IPOs are set to raise $1 billion in the upcoming week, which would make it the busiest five-day stretch for IPOs since the week of July 28. Shake Shack's IPO offers investors a chance to own a fast-growing fast casual concept based in New...
AVGR: 11.82 (+0.20), SHAK: 68.53 (+5.80), ASND: 20.00 (-0.86), HIFR: 31.27 (-0.37), REDX: (), ONCE: 61.39 (-0.66), ENTL: 27.43 (+0.44), ZSAN: 8.80 (-0.10), FLKS: 22.56 (-0.35), LENS: 7.38 (-0.62), TCON: 11.74 (-0.41)
